跳至主要内容
临床试验/NCT01244282
NCT01244282已完成1 期

A Pilot Clinical Trial to Study Arterial Spin Labeling and USPIO-enhanced MRI Methodologies for Measuring Hemodynamic Responses to Non-Drug Stimuli in Healthy Subjects

Merck Sharp & Dohme LLC0 个研究点目标入组 10 人开始时间: 2010年11月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
10
主要终点
Magnitude of the MRI percent signal change in response to sensory stimulation without administration of ferumoxytol (BOLD fMRI)

研究概览

简要总结

This study will identify a dose of ferumoxytol that can reliably detect changes in blood flow/volume in response to non-drug stimuli. The study will determine whether signal detection for functional magnetic resonance imaging (fMRI) using ferumoxytol is better than that for blood oxygen level-dependent (BOLD) fMRI in response to sensory stimulation. The following procedures will be conducted in each of two study periods: arterial spin labeling (ASL) imaging study with increasing exposure to carbon dioxide (CO2); BOLD fMRI study with sensory stimulation; MRI studies with sensory stimulation in the presence of increasing doses of ferumoxytol; MRI study with increasing exposure to CO2 in the presence of ferumoxytol. There will be a 3-week interval between the two study periods. The study will enroll 8 subjects, but an additional 4 subjects are permitted to enroll to preserve study power.

详细描述

Study Design: Translational Medicine - Imaging Platform Development

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
21 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Participant weighs approximately 55-75 kg and has a Body Mass Index (BMI) of 18-25 kg/m^2
  • Participant is in good health
  • Participant is a nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months

排除标准

  • Participant has a contraindication to MRI including cardiac pacemaker, brain aneurysm clip, implanted neurostimulator, insulin pump, cochlear implant, metal slivers in the eyes, or any other MRI-incompatible metal implants that cannot be safely removed
  • Participant has a condition that would limit his ability to complete MRI procedures, such as claustrophobia or chronic back pain
  • Participant plans to undergo MRI studies in the 3 months following the post-study visit
  • Participant has a history of hemochromatosis or other conditions of iron overload or disease of iron metabolism
  • Participant has a known sensitivity to ferumoxytol or iron-containing products or has a history of severe allergies, anaphylactic reaction, or intolerance to drugs and/or foods
  • Participant has a history of stroke, chronic seizures, or major neurological disorder
  • Participant is unable to refrain from the use of any medication, including prescription and non-prescription drugs or herbal remedies from approximately 2 weeks prior to the first dose of ferumoxytol until the post-study visit
  • Participant has a history of significant head injury/trauma with loss of consciousness lasting for 15 minutes and one or more of the following: a) recurring seizures resulting from head injury; b) persistent neurological or cognitive sequelae of the injury; c) cognitive rehabilitation following the injury

结局指标

主要结局

Magnitude of the MRI percent signal change in response to sensory stimulation without administration of ferumoxytol (BOLD fMRI)

时间窗: 45 minutes after initiation of imaging procedures

Magnitude of the MRI percent signal change in response to sensory stimulation following administration of the first dose of ferumoxytol (250 mg)

时间窗: 55 minutes after initiation of imaging procedures

Magnitude of the MRI percent signal change in response to sensory stimulation following administration of the second dose of ferumoxytol (100 mg, total cumulative dose of 350 mg)

时间窗: 70 minutes after initiation of imaging procedures

Magnitude of the MRI percent signal change in response to sensory stimulation following administration of the third dose of ferumoxytol (180 mg, total cumulative dose of 510 mg)

时间窗: 85 minutes after initiation of imaging procedures

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验